[ad_1]
Bavarian Nordic has signed a producing settlement with Serum Institute of India (SII), increasing its strategic partnership by a contract for its chikungunya vaccine (CHIKV VLP).
The contract covers a full expertise switch for the vaccine manufacturing course of from Bavarian Nordic to SII, aiming to extend manufacturing capability and future provide for endemic low- and middle-income international locations.
The brand new association builds upon the prevailing licence and manufacturing partnership between the 2 firms for the mpox vaccine.
It replaces an earlier cope with Organic E. Each events will even discover potential co-development alternatives as a part of this prolonged collaboration.
Bavarian Nordic’s president and CEO Paul Chaplin stated: “We’re happy to strengthen our strategic partnership with Serum Institute of India.
“By leveraging the strengths of each organisations, we will scale manufacturing of our chikungunya vaccine to broaden international provide and enhance entry for populations across the globe.”
The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product meant for energetic immunisation towards illness attributable to the chikungunya virus in individuals aged 12 years and above.
It’s designed to set off a powerful seroresponse, with protecting immunity starting to develop as quickly as one week following vaccination.
Because it doesn’t include viral genetic materials, the vaccine is non-infectious and can’t trigger illness, making it appropriate for a broad inhabitants demographic.
Marketed as Vimkunya, CHIKV VLP has obtained approval from the UK’s Medicines and Healthcare merchandise Regulatory Company (MHRA), the European Fee, and the US Meals and Drug Administration (FDA) in 2025.
Regulatory overview is underway in Canada and Switzerland.
In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, within the UK.
The launch adopted a big enhance in travel-related illness instances reported nationwide. The UK Well being Safety Company (UKHSA) said that incidences rose by 170% in August 2025 in contrast with the identical interval in 2024.
“Bavarian Nordic and SII signal settlement for chikungunya vaccine manufacturing” was initially created and printed by Pharmaceutical Expertise, a GlobalData owned model.
The knowledge on this website has been included in good religion for common informational functions solely. It’s not meant to quantity to recommendation on which you must rely, and we give no illustration, guarantee or assure, whether or not specific or implied as to its accuracy or completeness. You have to acquire skilled or specialist recommendation earlier than taking, or refraining from, any motion on the premise of the content material on our website.
[ad_2]
